DE3585252D1
(de)
|
1984-07-06 |
1992-03-05 |
Fisons Plc |
Benzimidazole, und verfahren zu deren herstellung, deren formulierung und verwendung als magensaeuresekretionshemmende verbindungen.
|
CA1327010C
(en)
*
|
1986-02-13 |
1994-02-15 |
Tadashi Makino |
Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
|
CA1276017C
(en)
*
|
1986-02-13 |
1990-11-06 |
Takeda Chemical Industries, Ltd. |
Sulfenamide derivatives and their production
|
US6749864B2
(en)
|
1986-02-13 |
2004-06-15 |
Takeda Chemical Industries, Ltd. |
Stabilized pharmaceutical composition
|
US5433959A
(en)
|
1986-02-13 |
1995-07-18 |
Takeda Chemical Industries, Ltd. |
Stabilized pharmaceutical composition
|
DK171989B1
(da)
*
|
1987-08-04 |
1997-09-08 |
Takeda Chemical Industries Ltd |
Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
|
EP0415990A1
(de)
*
|
1988-05-25 |
1991-03-13 |
Byk Gulden Lomberg Chemische Fabrik GmbH |
Neue fluoralkoxyverbindungen
|
JP2536173B2
(ja)
*
|
1988-08-18 |
1996-09-18 |
武田薬品工業株式会社 |
注射剤
|
US5223515A
(en)
*
|
1988-08-18 |
1993-06-29 |
Takeda Chemical Industries, Ltd. |
Injectable solution containing a pyridyl methylsulfinylbenzimidazole
|
AT391693B
(de)
*
|
1988-11-15 |
1990-11-12 |
Cl Pharma |
Verfahren zur herstellung von 3-5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer
|
SE8804629D0
(sv)
|
1988-12-22 |
1988-12-22 |
Ab Haessle |
New therapeutically active compounds
|
SE8804628D0
(sv)
|
1988-12-22 |
1988-12-22 |
Ab Haessle |
New compounds
|
IE64199B1
(en)
*
|
1988-12-22 |
1995-07-12 |
Haessle Ab |
Compound with gastric acid inhibitory effect and process for its preparation
|
DK0382489T3
(da)
*
|
1989-02-10 |
1995-01-16 |
Takeda Chemical Industries Ltd |
Monoklonalt anti-humant papillomvirusantistof, hybridomcelle, der producerer dette, samt fremgangsmåde til fremstilling deraf
|
US4965269A
(en)
*
|
1989-12-20 |
1990-10-23 |
Ab Hassle |
Therapeutically active chloro substituted benzimidazoles
|
US5274099A
(en)
*
|
1989-12-20 |
1993-12-28 |
Aktiebolaget Hassle |
Therapeutically active fluoro substituted benzimidazoles
|
US5049674A
(en)
*
|
1989-12-20 |
1991-09-17 |
Aktiebolaget Hassle |
Therapeutically active fluoro substituted benzimidazoles
|
EP0481764B1
(en)
|
1990-10-17 |
2000-03-29 |
Takeda Chemical Industries, Ltd. |
Pyridine derivatives, their production and use
|
TW209174B
(uk)
|
1991-04-19 |
1993-07-11 |
Takeda Pharm Industry Co Ltd |
|
WO1993006097A1
(en)
*
|
1991-09-20 |
1993-04-01 |
Merck & Co., Inc. |
Novel process for the preparation of anti-ulcer agents
|
ES2036948B1
(es)
*
|
1991-11-21 |
1994-09-01 |
Genesis Para La Investigacion |
Procedimiento de obtencion de compuestos derivados de piridina.
|
CA2138787A1
(en)
*
|
1992-07-08 |
1994-01-20 |
Clifton Augustus Baile |
Alleviating stomach ulcers in swine
|
KR100258423B1
(ko)
*
|
1992-07-28 |
2000-07-01 |
클래스 빌헬름슨 |
오메프라졸 및 그의 동족체를 함유하는 주사제 및 주사제 키트
|
ATE178603T1
(de)
*
|
1993-02-17 |
1999-04-15 |
Byk Gulden Lomberg Chem Fab |
Substituierte heteroarylalkylthiopyridine zur bekämpfung von helicobacter bakterien
|
ES2060541B1
(es)
*
|
1993-02-26 |
1995-11-16 |
Vinas Lab |
Nuevo procedimiento para la sintesis de un derivado de 2-(2-piridilmetilsufinil) bencimidazol, y nuevos productos intermedios obtenidos con el mismo.
|
ES2063705B1
(es)
*
|
1993-06-14 |
1995-07-16 |
S A L V A T Lab Sa |
Intermedio para la sintesis de lansoprazol y su procedimiento de obtencion.
|
TW280770B
(uk)
*
|
1993-10-15 |
1996-07-11 |
Takeda Pharm Industry Co Ltd |
|
US5374730A
(en)
*
|
1993-11-04 |
1994-12-20 |
Torcan Chemical Ltd. |
Preparation of omeprazole and lansoprazole
|
US5502195A
(en)
*
|
1993-11-04 |
1996-03-26 |
Slemon; Clarke |
Sulfoxide-carboxylate intermediates of omeprazole and lansoprazole
|
CN1048980C
(zh)
*
|
1994-03-29 |
2000-02-02 |
广东汕头鮀滨化学药业总公司 |
一种新的吡啶衍生物及其制备方法和应用
|
SE9402431D0
(sv)
*
|
1994-07-08 |
1994-07-08 |
Astra Ab |
New tablet formulation
|
GB9423968D0
(en)
*
|
1994-11-28 |
1995-01-11 |
Astra Ab |
Resolution
|
SE9500422D0
(sv)
*
|
1995-02-06 |
1995-02-06 |
Astra Ab |
New oral pharmaceutical dosage forms
|
SE9500478D0
(sv)
*
|
1995-02-09 |
1995-02-09 |
Astra Ab |
New pharmaceutical formulation and process
|
US5708017A
(en)
*
|
1995-04-04 |
1998-01-13 |
Merck & Co., Inc. |
Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
|
HRP960232A2
(en)
*
|
1995-07-03 |
1998-02-28 |
Astra Ab |
A process for the optical purification of compounds
|
US5824339A
(en)
*
|
1995-09-08 |
1998-10-20 |
Takeda Chemical Industries, Ltd |
Effervescent composition and its production
|
DE69631981T2
(de)
*
|
1995-09-21 |
2005-04-14 |
Pharma Pass Ii Llc, Irvine |
Lansoprazolhaltige Arzneizusammensetzung und Herstellungsverfahren
|
SE521100C2
(sv)
*
|
1995-12-15 |
2003-09-30 |
Astra Ab |
Förfarande för framställning av en bensimidazolförening
|
US6645988B2
(en)
*
|
1996-01-04 |
2003-11-11 |
Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and method of using same
|
US5840737A
(en)
|
1996-01-04 |
1998-11-24 |
The Curators Of The University Of Missouri |
Omeprazole solution and method for using same
|
US6699885B2
(en)
*
|
1996-01-04 |
2004-03-02 |
The Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and methods of using same
|
US6489346B1
(en)
*
|
1996-01-04 |
2002-12-03 |
The Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and method of using same
|
SE9600070D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
US6599927B2
(en)
|
1996-10-11 |
2003-07-29 |
Astrazeneca Ab |
Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
|
TW385306B
(en)
*
|
1996-11-14 |
2000-03-21 |
Takeda Chemical Industries Ltd |
Method for producing crystals of benzimidazole derivatives
|
WO1998054172A1
(en)
*
|
1997-05-30 |
1998-12-03 |
Dr. Reddy's Research Foundation |
Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
|
DE69827392T2
(de)
|
1997-07-25 |
2005-10-27 |
Altana Pharma Ag |
Protonenpumpenhemmer als kombinationstherapeutika mit antibakteriell wirkenden substanzen
|
SE9704870D0
(sv)
*
|
1997-12-22 |
1997-12-22 |
Astra Ab |
New pharmaceutical formulation I
|
CN1195500C
(zh)
|
1998-05-18 |
2005-04-06 |
武田药品工业株式会社 |
可口腔崩解的片剂
|
ZA9810765B
(en)
*
|
1998-05-28 |
1999-08-06 |
Ranbaxy Lab Ltd |
Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
|
IE990506A1
(en)
*
|
1998-06-26 |
2000-11-15 |
Russinsky Ltd |
Pyridine Building Blocks
|
SI20019A
(sl)
*
|
1998-07-13 |
2000-02-29 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
|
ES2182554T3
(es)
*
|
1998-07-22 |
2003-03-01 |
Sepracor Inc |
Composiciones farmaceuticas que comprenden hiddroxilansoprazol y uso de las mismas.
|
US6093734A
(en)
*
|
1998-08-10 |
2000-07-25 |
Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin |
Prodrugs of proton pump inhibitors
|
BR9912937A
(pt)
|
1998-08-10 |
2001-05-08 |
Partnership Of Michael E Garst |
Pró-drogas de inibidores de bomba de prótons
|
ATE321538T1
(de)
|
1998-08-12 |
2006-04-15 |
Altana Pharma Ag |
Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole
|
DE19843413C1
(de)
*
|
1998-08-18 |
2000-03-30 |
Byk Gulden Lomberg Chem Fab |
Neue Salzform von Pantoprazol
|
JP3926936B2
(ja)
|
1998-11-16 |
2007-06-06 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スルホキシド誘導体・アセトン錯体およびその製造法
|
US20040224989A1
(en)
*
|
1999-01-29 |
2004-11-11 |
Barberich Timothy J. |
S-lansoprazole compositions and methods
|
US6852739B1
(en)
*
|
1999-02-26 |
2005-02-08 |
Nitromed Inc. |
Methods using proton pump inhibitors and nitric oxide donors
|
TWI243672B
(en)
|
1999-06-01 |
2005-11-21 |
Astrazeneca Ab |
New use of compounds as antibacterial agents
|
PT1187601E
(pt)
|
1999-06-07 |
2005-11-30 |
Altana Pharma Ag |
Nova forma de preparacao e a administracao compreendendo um inibidor da bomba de protoes instavel em meio acido
|
TWI289557B
(en)
|
1999-06-17 |
2007-11-11 |
Takeda Chemical Industries Ltd |
A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
|
WO2001002389A1
(fr)
*
|
1999-06-30 |
2001-01-11 |
Takeda Chemical Industries, Ltd. |
Cristaux de composes benzimidazole
|
US6245913B1
(en)
|
1999-06-30 |
2001-06-12 |
Wockhardt Europe Limited |
Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
|
US6312723B1
(en)
|
1999-08-26 |
2001-11-06 |
Robert R. Whittle |
Pharmaceutical unit dosage form
|
US6262085B1
(en)
|
1999-08-26 |
2001-07-17 |
Robert R. Whittle |
Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
|
US6262086B1
(en)
|
1999-08-26 |
2001-07-17 |
Robert R. Whittle |
Pharmaceutical unit dosage form
|
US6369087B1
(en)
|
1999-08-26 |
2002-04-09 |
Robert R. Whittle |
Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
|
US6268385B1
(en)
|
1999-08-26 |
2001-07-31 |
Robert R. Whittle |
Dry blend pharmaceutical formulations
|
US6326384B1
(en)
|
1999-08-26 |
2001-12-04 |
Robert R. Whittle |
Dry blend pharmaceutical unit dosage form
|
US6312712B1
(en)
|
1999-08-26 |
2001-11-06 |
Robert R. Whittle |
Method of improving bioavailability
|
US6316020B1
(en)
|
1999-08-26 |
2001-11-13 |
Robert R. Whittle |
Pharmaceutical formulations
|
US6780880B1
(en)
|
1999-08-26 |
2004-08-24 |
Robert R. Whittle |
FT-Raman spectroscopic measurement
|
US6228400B1
(en)
|
1999-09-28 |
2001-05-08 |
Carlsbad Technology, Inc. |
Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
|
KR100359256B1
(ko)
*
|
1999-10-06 |
2002-11-04 |
한미약품공업 주식회사 |
란소프라졸의 개선된 제조방법
|
SE9903831D0
(sv)
*
|
1999-10-22 |
1999-10-22 |
Astra Ab |
Formulation of substituted benzimidazoles
|
US20060034937A1
(en)
*
|
1999-11-23 |
2006-02-16 |
Mahesh Patel |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
US20030180352A1
(en)
*
|
1999-11-23 |
2003-09-25 |
Patel Mahesh V. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
US7732404B2
(en)
|
1999-12-30 |
2010-06-08 |
Dexcel Ltd |
Pro-nanodispersion for the delivery of cyclosporin
|
SE0000774D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
New formulation
|
ES2171116B1
(es)
*
|
2000-04-14 |
2003-08-01 |
Esteve Quimica Sa |
Procedimiento para la obtencion de derivados de (((piridil sustituido)metil)tio)bencimidazol.
|
KR101035534B1
(ko)
*
|
2000-05-15 |
2011-05-23 |
다케다 야쿠힌 고교 가부시키가이샤 |
결정의 제조방법
|
CA2417311C
(en)
|
2000-08-04 |
2012-07-10 |
Takeda Chemical Industries, Ltd. |
Crystalline alkali metal salts of lansoprazole and their production and use
|
US6544556B1
(en)
|
2000-09-11 |
2003-04-08 |
Andrx Corporation |
Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
|
AU2001296908A1
(en)
*
|
2000-09-29 |
2002-04-08 |
Geneva Pharmaceuticals, Inc. |
Proton pump inhibitor formulation
|
KR100887912B1
(ko)
*
|
2000-12-01 |
2009-03-12 |
다케다 야쿠힌 고교 가부시키가이샤 |
(r)- 또는 (s)-란소프라졸의 결정화 방법
|
AU2002231654A1
(en)
|
2000-12-07 |
2002-06-18 |
Byk Gulden Lomberg Chemische Fabrik G.M.B.H. |
Pharmaceutical paste comprising an acid-labile active ingredient
|
KR20030059318A
(ko)
|
2000-12-07 |
2003-07-07 |
알타나 파마 아게 |
산 불안정성 활성 성분을 포함하는 현탁액 형태의 약학 제제
|
EP1341528B1
(en)
|
2000-12-07 |
2012-01-18 |
Nycomed GmbH |
Rapidly disintegrating tablet comprising an acid-labile active ingredient
|
KR100430575B1
(ko)
*
|
2001-02-21 |
2004-05-10 |
주식회사 씨트리 |
란소프라졸 및 그 중간체의 제조방법
|
US6645946B1
(en)
|
2001-03-27 |
2003-11-11 |
Pro-Pharmaceuticals, Inc. |
Delivery of a therapeutic agent in a formulation for reduced toxicity
|
SE0101379D0
(sv)
|
2001-04-18 |
2001-04-18 |
Diabact Ab |
Komposition som hämmar utsöndring av magsyra
|
US8206741B2
(en)
|
2001-06-01 |
2012-06-26 |
Pozen Inc. |
Pharmaceutical compositions for the coordinated delivery of NSAIDs
|
SE0102993D0
(sv)
|
2001-09-07 |
2001-09-07 |
Astrazeneca Ab |
New self emulsifying drug delivery system
|
AU2002332178B2
(en)
*
|
2001-09-18 |
2005-12-08 |
Zeria Pharmaceutical Co., Ltd. |
Benzimidazole derivatives
|
EP1437352A4
(en)
*
|
2001-09-25 |
2004-12-08 |
Takeda Chemical Industries Ltd |
BENZYMIDAZOLE COMPOUND, PROCESS FOR PRODUCING AND USING THE SAME
|
US9358214B2
(en)
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
US8101209B2
(en)
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
CN100562317C
(zh)
|
2001-10-17 |
2009-11-25 |
武田药品工业株式会社 |
含大量酸不稳定药物的颗粒
|
SE0104295D0
(sv)
*
|
2001-12-18 |
2001-12-18 |
Astrazeneca Ab |
New process
|
DE60325709D1
(de)
|
2002-04-09 |
2009-02-26 |
Flamel Tech Sa |
Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
|
CA2480824A1
(fr)
|
2002-04-09 |
2003-10-16 |
Flamel Technologies |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
|
US20030228363A1
(en)
*
|
2002-06-07 |
2003-12-11 |
Patel Mahendra R. |
Stabilized pharmaceutical compositons containing benzimidazole compounds
|
KR100873419B1
(ko)
*
|
2002-06-18 |
2008-12-11 |
페어차일드코리아반도체 주식회사 |
높은 항복 전압, 낮은 온 저항 및 작은 스위칭 손실을갖는 전력용 반도체 소자
|
RU2292342C2
(ru)
*
|
2002-07-19 |
2007-01-27 |
Уинстон Фармасьютикалс ЛЛС. |
Производные бензимидазола и их применение в качестве пролекарств ингибиторов протонного насоса
|
TW200410955A
(en)
|
2002-07-29 |
2004-07-01 |
Altana Pharma Ag |
Novel salt of (S)-PANTOPRAZOLE
|
CA2493618A1
(en)
*
|
2002-08-01 |
2004-02-12 |
Nitromed, Inc. |
Nitrosated proton pump inhibitors, compositions and methods of use
|
PT1501824E
(pt)
*
|
2002-08-21 |
2007-11-28 |
Teva Pharma |
Método para purificação de lansoprazole
|
NZ538954A
(en)
|
2002-08-30 |
2007-04-27 |
Altana Pharma Ag |
The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis and allergic conjunctivitis
|
MY148805A
(en)
|
2002-10-16 |
2013-05-31 |
Takeda Pharmaceutical |
Controlled release preparation
|
US8697094B2
(en)
|
2002-10-16 |
2014-04-15 |
Takeda Pharmaceutical Company Limited |
Stable solid preparations
|
SE0203065D0
(sv)
|
2002-10-16 |
2002-10-16 |
Diabact Ab |
Gastric acid secretion inhibiting composition
|
EP1743893A1
(en)
|
2002-11-18 |
2007-01-17 |
Teva Pharmaceutical Industries Ltd. |
Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol
|
DE03789888T1
(de)
*
|
2002-11-18 |
2005-08-18 |
Teva Pharmaceutical Industries Ltd. |
Stabiles lansoprazol, enthaltend mehr als 500 ppm bis zu 3000 ppm wasser und mehr als 200 ppm bis zu 5000 ppm alkohol
|
DE10254167A1
(de)
|
2002-11-20 |
2004-06-09 |
Icon Genetics Ag |
Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
|
BRPI0310118B1
(pt)
|
2002-12-06 |
2015-10-20 |
Altana Pharma Ag |
processo para a preparação de inibidores de bomba de próton (ppi) opticamente puro possuindo uma estrutura de sulfinila
|
DK1575941T3
(da)
|
2002-12-06 |
2012-07-09 |
Nycomed Gmbh |
Fremgangsmåde til fremstilling af (S)-pantoprazol
|
JP2006514108A
(ja)
*
|
2002-12-19 |
2006-04-27 |
テバ ファーマシューティカル インダストリーズ リミティド |
パントプラゾールナトリウムの固体状態、それらの調製方法、及び公知のパントプラゾールナトリウム水和物の調製方法
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
US7678816B2
(en)
*
|
2003-02-05 |
2010-03-16 |
Teva Pharmaceutical Industries Ltd. |
Method of stabilizing lansoprazole
|
US20050220870A1
(en)
*
|
2003-02-20 |
2005-10-06 |
Bonnie Hepburn |
Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
|
EP1602362B1
(en)
|
2003-03-12 |
2016-09-28 |
Takeda Pharmaceutical Company Limited |
Drug composition having active ingredient adhered at high concentration to spherical core
|
ES2245277T1
(es)
*
|
2003-03-12 |
2006-01-01 |
Teva Pharmaceutical Industries Limited |
Solidos cristalinos y amorfos de pantoprazol y procedimientos para su preparacion.
|
US7608625B2
(en)
*
|
2003-03-13 |
2009-10-27 |
Eisai R & D Management Co., Ltd. |
Method for treating bruxism and bruxism-related diseases
|
CA2523218A1
(en)
*
|
2003-04-22 |
2004-11-04 |
Dr. Reddy's Laboratories Limited |
Oral pharmaceutical formulations of acid-labile active ingredients and process for making same
|
PE20050150A1
(es)
|
2003-05-08 |
2005-03-22 |
Altana Pharma Ag |
Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
|
CL2004000983A1
(es)
|
2003-05-08 |
2005-03-04 |
Altana Pharma Ag |
Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
|
US7683177B2
(en)
*
|
2003-06-10 |
2010-03-23 |
Teva Pharmaceutical Industries Ltd |
Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
|
US8802139B2
(en)
*
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
BRPI0412590A
(pt)
*
|
2003-07-15 |
2006-09-19 |
Allergan Inc |
processo para preparação de pró-drogas isomericamente puras de inibidores de bomba de próton
|
US8993599B2
(en)
|
2003-07-18 |
2015-03-31 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
WO2005020954A2
(en)
*
|
2003-09-03 |
2005-03-10 |
Agi Therapeutics Limited |
Proton pump inhibitor formulations, and methods of preparing and using such formulations
|
TWI372066B
(en)
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
US20050075371A1
(en)
*
|
2003-10-03 |
2005-04-07 |
Allergan, Inc. |
Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
|
WO2005039640A1
(en)
*
|
2003-10-03 |
2005-05-06 |
Allergan Inc. |
Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
|
JP2007522217A
(ja)
*
|
2004-02-10 |
2007-08-09 |
サンタラス インコーポレイティッド |
プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
|
GB0403165D0
(en)
*
|
2004-02-12 |
2004-03-17 |
Ct |
Novel uses for proton pump inhibitors
|
US20070161679A1
(en)
*
|
2004-02-18 |
2007-07-12 |
Allergan, Inc. |
Method and compositions for the intravenous administration of compounds related to proton pump inhibitors
|
JP2007523163A
(ja)
*
|
2004-02-18 |
2007-08-16 |
アラーガン、インコーポレイテッド |
プロトンポンプインヒビターのプロドラッグの投与のための方法および組成物
|
CA2558535A1
(en)
*
|
2004-03-03 |
2005-10-06 |
Teva Pharmaceutical Industries Ltd. |
A stable pharmaceutical composition comprising an acid labile drug
|
CA2561700A1
(en)
*
|
2004-04-16 |
2005-12-15 |
Santarus, Inc. |
Combination of proton pump inhibitor, buffering agent, and prokinetic agent
|
WO2005105799A1
(en)
*
|
2004-04-28 |
2005-11-10 |
Altana Pharma Ag |
Dialkoxy-imidazopyridines derivatives
|
US8815916B2
(en)
|
2004-05-25 |
2014-08-26 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
US8906940B2
(en)
|
2004-05-25 |
2014-12-09 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
JP5563735B2
(ja)
|
2004-06-16 |
2014-07-30 |
タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド |
Ppi多回剤形
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US20060024362A1
(en)
*
|
2004-07-29 |
2006-02-02 |
Pawan Seth |
Composition comprising a benzimidazole and process for its manufacture
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
JP5173191B2
(ja)
|
2004-09-13 |
2013-03-27 |
武田薬品工業株式会社 |
酸化化合物の製造方法及び製造装置
|
US8747895B2
(en)
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
EP1802285B1
(en)
*
|
2004-10-21 |
2013-02-27 |
Aptalis Pharmatech, Inc. |
Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
|
US20060105038A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Eurand Pharmaceuticals Limited |
Taste-masked pharmaceutical compositions prepared by coacervation
|
WO2006053383A1
(en)
|
2004-11-22 |
2006-05-26 |
Anadis Ltd |
Bioactive compositions
|
EP1681056A1
(en)
|
2005-01-14 |
2006-07-19 |
Krka Tovarna Zdravil, D.D., Novo Mesto |
Process for preparing lansoprazole
|
WO2006090845A1
(ja)
|
2005-02-25 |
2006-08-31 |
Takeda Pharmaceutical Company Limited |
顆粒の製造方法
|
KR100771659B1
(ko)
|
2005-03-23 |
2007-10-30 |
주식회사 카이로제닉스 |
판토프라졸 및 그 중간체의 제조방법
|
US9161918B2
(en)
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
US7981908B2
(en)
|
2005-05-11 |
2011-07-19 |
Vecta, Ltd. |
Compositions and methods for inhibiting gastric acid secretion
|
US7803817B2
(en)
|
2005-05-11 |
2010-09-28 |
Vecta, Ltd. |
Composition and methods for inhibiting gastric acid secretion
|
EP1889841A4
(en)
|
2005-06-07 |
2010-04-07 |
Takeda Pharmaceutical |
CRYSTAL OF A SALT OF A BENZIMIDAZOLE COMPOUND
|
CA2611917A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Takeda Pharmaceutical Company Limited |
Injection
|
US7601737B2
(en)
|
2005-07-26 |
2009-10-13 |
Nycomed Gmbh |
Isotopically substituted proton pump inhibitors
|
CN101309917B
(zh)
*
|
2005-10-06 |
2013-09-11 |
奥斯拜客斯制药有限公司 |
具有增强治疗性质的胃h+,k+-atp酶氘代抑制剂
|
GB0525710D0
(en)
*
|
2005-12-17 |
2006-01-25 |
Pliva Hrvatska D O O |
An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
ZA200805646B
(en)
|
2005-12-28 |
2009-12-30 |
Takeda Pharmaceutical |
Controlled release solid preparation
|
WO2007074856A1
(ja)
|
2005-12-28 |
2007-07-05 |
Takeda Pharmaceutical Company Limited |
口腔内崩壊性固形製剤の製造法
|
AU2007225935B2
(en)
*
|
2006-03-10 |
2011-12-22 |
Link Genomics, Inc. |
Novel pyridine derivative having anti-Helicobacter pylori activity
|
CN101453993A
(zh)
|
2006-04-03 |
2009-06-10 |
伊萨·奥迪迪 |
含有机溶胶涂层的受控释放递送物件
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
EP2026768B1
(en)
*
|
2006-06-01 |
2018-02-28 |
Dexcel Pharma Technologies Ltd. |
Multiple unit pharmaceutical formulation
|
US7863330B2
(en)
|
2006-06-14 |
2011-01-04 |
Rottapharm S.P.A. |
Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
|
PL2046334T3
(pl)
|
2006-07-25 |
2015-02-27 |
Vecta Ltd |
Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI
|
WO2008036201A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Alevium Pharmaceuticals, Inc. |
Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
|
US8129536B2
(en)
*
|
2006-09-22 |
2012-03-06 |
Orchid Chemicals & Pharmaceuticals Limited |
Method for the purification of lansoprazole
|
WO2008067037A2
(en)
|
2006-10-05 |
2008-06-05 |
Santarus, Inc. |
Novel formulations of proton pump inhibitors and methods of using these formulations
|
EP2086543A2
(en)
|
2006-10-27 |
2009-08-12 |
The Curators of the University of Missouri |
Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
|
US9205094B2
(en)
|
2006-12-22 |
2015-12-08 |
Ironwood Pharmaceuticals, Inc. |
Compositions comprising bile acid sequestrants for treating esophageal disorders
|
JP5366558B2
(ja)
|
2006-12-28 |
2013-12-11 |
武田薬品工業株式会社 |
口腔内崩壊性固形製剤
|
WO2008087665A2
(en)
*
|
2007-01-18 |
2008-07-24 |
Matrix Laboratories Ltd |
Process for preparation of lansoprazole
|
US20080194307A1
(en)
*
|
2007-02-13 |
2008-08-14 |
Jeff Sanger |
Sports-based game of chance
|
TW200840574A
(en)
*
|
2007-04-02 |
2008-10-16 |
Univ Nat Taiwan |
The pharmaceutical component for treating hearing loss disease
|
US20100210847A1
(en)
*
|
2007-07-17 |
2010-08-19 |
Ranbaxy Laboratories Limited |
Process for the preparation of pantoprazole sodium and pantoprazole sodium sesquihydrate
|
US8173158B2
(en)
|
2007-10-12 |
2012-05-08 |
Takeda Pharmaceuticals U.S.A., Inc. |
Methods of treating gastrointestinal disorders independent of the intake of food
|
AU2008346115A1
(en)
*
|
2007-12-18 |
2009-07-16 |
Watson Pharma Private Limited |
A process for preparation of stable amorphous R-lansoprazole
|
US20100286400A1
(en)
|
2007-12-31 |
2010-11-11 |
Takeda Pharmaceutical Company Limited |
Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
|
CA2716367C
(en)
|
2008-02-20 |
2015-05-26 |
The Curators Of The University Of Missouri |
Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
|
US20090227633A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Bassam Damaj |
Methods to inhibit tumor cell growth by using proton pump inhibitors
|
EP2262790B1
(en)
|
2008-03-10 |
2017-06-07 |
Takeda Pharmaceutical Company Limited |
Crystal of benzimidazole compound
|
US20090263475A1
(en)
*
|
2008-04-21 |
2009-10-22 |
Nagaraju Manne |
Dexlansoprazole compositions
|
AU2009336561A1
(en)
|
2008-05-14 |
2010-07-15 |
Watson Pharma Private Limited |
Stable R-(+)-lansoprazole amine salt and a process for preparing the same
|
AU2009290712A1
(en)
|
2008-09-09 |
2010-03-18 |
Astrazeneca Ab |
Method for delivering a pharmaceutical composition to patient in need thereof
|
US20100113527A1
(en)
*
|
2008-09-30 |
2010-05-06 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of dexlansoprazole
|
US20100093747A1
(en)
*
|
2008-10-10 |
2010-04-15 |
Erica Brook Goodhew |
Method of inducing negative chemotaxis
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
WO2010122583A2
(en)
|
2009-04-24 |
2010-10-28 |
Rubicon Research Private Limited |
Oral pharmaceutical compositions of acid labile substances
|
WO2010134099A1
(en)
|
2009-05-21 |
2010-11-25 |
Cadila Healthcare Limited |
One pot process for preparing omeprazole and related compounds
|
WO2011004387A2
(en)
|
2009-06-18 |
2011-01-13 |
Matrix Laboratories Ltd |
Process for the preparation of dexlansoprazole polymorphic forms
|
WO2010151216A1
(en)
|
2009-06-25 |
2010-12-29 |
Astrazeneca Ab |
Method for treating a patient at risk for developing an nsaid-associated ulcer
|
TWI471146B
(zh)
|
2009-12-02 |
2015-02-01 |
Aptalis Pharma Ltd |
菲索特芬那定(fexofenadine)微膠囊及包含其之組合物
|
WO2011080502A2
(en)
|
2009-12-29 |
2011-07-07 |
Orexo Ab |
New pharmaceutical dosage form for the treatment of gastric acid-related disorders
|
EP2519229A2
(en)
|
2009-12-29 |
2012-11-07 |
Novartis AG |
New pharmaceutical dosage form for the treatment of gastric acid-related disorders
|
WO2011080500A2
(en)
|
2009-12-29 |
2011-07-07 |
Orexo Ab |
New pharmaceutical dosage form for the treatment of gastric acid-related disorders
|
US20110212171A1
(en)
*
|
2010-01-08 |
2011-09-01 |
Eurand, Inc. |
Taste masked topiramate composition and an orally disintegrating tablet comprising the same
|
US20110189271A1
(en)
*
|
2010-02-02 |
2011-08-04 |
Vishal Lad |
Pharmaceutical formulations of acid-labile drugs
|
US20130202688A1
(en)
|
2010-05-04 |
2013-08-08 |
Sunilendu Bhushan Roy |
Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
|
US20130216617A1
(en)
|
2010-06-29 |
2013-08-22 |
Cadila Healthcare Limited |
Pharmaceutical compositions of (r)-lansoprazole
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
US9034858B2
(en)
|
2010-11-30 |
2015-05-19 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9358241B2
(en)
|
2010-11-30 |
2016-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
MX2013006247A
(es)
|
2010-12-03 |
2014-01-31 |
Takeda Pharmaceutical |
Tableta oralmente desintegradora.
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
WO2012091153A2
(en)
|
2010-12-27 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Orally disintegrating tablet
|
US9233103B2
(en)
|
2011-03-25 |
2016-01-12 |
Takeda Pharmaceuticals U.S.A., Inc. |
Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
|
JP5925318B2
(ja)
|
2011-11-30 |
2016-05-25 |
武田薬品工業株式会社 |
有核錠
|
EP2601947A1
(en)
|
2011-12-05 |
2013-06-12 |
Abo Bakr Mohammed Ali Al-Mehdar |
Fixed-dose combination for treatment of helicobacter pylori associated diseases
|
KR20140113667A
(ko)
|
2011-12-16 |
2014-09-24 |
아토픽스 테라퓨릭스 리미티드 |
호산구성 식도염의 치료를 위한 crth2 길항제 및 양성자 펌프 저해제의 조합
|
CA2860231A1
(en)
|
2011-12-28 |
2013-07-04 |
Pozen Inc. |
Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
|
CN104203938A
(zh)
|
2012-01-21 |
2014-12-10 |
朱比兰特生命科学有限公司 |
用于制备2-吡啶基甲基亚硫酰基苯并咪唑、它们的类似物和光学活性对映体的方法
|
EP2945614B1
(en)
|
2013-01-15 |
2021-11-24 |
Ironwood Pharmaceuticals, Inc. |
Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
|
US10004691B2
(en)
|
2013-05-21 |
2018-06-26 |
Takeda Pharmaceuticals Company Limited |
Orally disintegrable tablet
|
US9457011B2
(en)
|
2014-02-25 |
2016-10-04 |
Muslim D. Shahid |
Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor
|
WO2016033549A2
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
US9498485B2
(en)
|
2014-08-28 |
2016-11-22 |
Lipocine Inc. |
Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
|
WO2016126625A1
(en)
|
2015-02-03 |
2016-08-11 |
Ironwood Pharmaceuticals, Inc. |
Methods of treating upper gastrointestinal disorders in ppi refractory gerd
|
US20170042806A1
(en)
|
2015-04-29 |
2017-02-16 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
WO2017145146A1
(en)
|
2016-02-25 |
2017-08-31 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising proton pump inhibitors
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
EP3544614A4
(en)
|
2016-11-28 |
2020-08-05 |
Lipocine Inc. |
ORAL TESTOSTERONE UNDECANOATE THERAPY
|
CN107365300B
(zh)
*
|
2017-07-26 |
2019-08-02 |
桂林华信制药有限公司 |
一种有效去除兰索拉唑粗品中杂质的方法
|
CN114163419A
(zh)
*
|
2021-12-24 |
2022-03-11 |
辰欣药业股份有限公司 |
一种兰索拉唑的制备方法
|
WO2024075017A1
(en)
|
2022-10-04 |
2024-04-11 |
Zabirnyk Arsenii |
Inhibition of aortic valve calcification
|